Validation of a rat behavioral avoidance model from a drug delivery perspective

Area of Science:

• Pharmacology
• Drug Development
• Sensory Science

Background:

• Taste-masking pharmaceuticals is crucial but challenging for specific formulations like sublingual tablets.
• Limited toxicological data in early drug development phases hinders human taste panel studies.
• Bitter taste perception poses a significant business risk in pharmaceutical development.

Purpose of the Study:

• To validate a rat behavioral avoidance model for identifying bitter-tasting compounds.
• To assess the model's sensitivity in detecting bitter-tasting drugs at relevant concentrations.
• To establish a reliable surrogate assay for early identification of taste-related formulation challenges.

Main Methods:

• Utilized a rat behavioral avoidance model to assess taste perception.
• Tested five compounds (ergotamine tartrate, fluoxetine, sucrose, sumatriptan, povidone) representing a range of taste profiles.
• Validated the model's sensitivity against known bitter and non-bitter substances.

Main Results:

• The rat behavioral avoidance model successfully identified known bitter-tasting compounds.
• The model demonstrated sensitivity in distinguishing between compounds with varying taste profiles.
• Bitter taste was accurately detected for compounds like ergotamine tartrate and fluoxetine.

Conclusions:

• The validated rat behavioral avoidance model serves as a useful surrogate for identifying potentially bitter pharmaceutical compounds.
• This assay can mitigate business risks by enabling early detection of taste issues.
• The model supports formulation development, especially for challenging dosage forms like rapid dissolve sublingual tablets.